22.418 articles found

USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF A-SYNUCLEINOPATHIES

MCLAURIN JOANNE.

· 2008-04-11

USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF ALPHA-SYNUCLEINOPATHIES

MCLAURIN JOANNE.

· 2008-04-11

Therapeutic strategies for Parkinson's disease: the ancient meets the future--traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells.

Wang X, Liang XB, Li FQ, Zhou HF, Liu XY, Wang JJ, Wang XM.

Neurochem Res · 2008-04-11

DOI: 10.1007/s11064-008-9691-zPMID: 18404373

Frequency and treatment of depressive symptoms in a Parkinson's disease registry.

Althaus A, Becker OA, Spottke A, Dengler R, Schneider F, Kloss M, Eggert K, Oertel WH, Dillmann U, Herting B, Classen J, Dodel R.

Parkinsonism Relat Disord · 2008-04-11

DOI: 10.1016/j.parkreldis.2008.01.016PMID: 18406197

Deep brain stimulation activation volumes and their association with neurophysiological mapping and therapeutic outcomes.

Maks CB, Butson CR, Walter BL, Vitek JL, McIntyre CC.

J Neurol Neurosurg Psychiatry · 2008-04-10

DOI: 10.1136/jnnp.2007.126219PMID: 18403440

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, Aminoff MJ.

Neurology · 2008-04-09

DOI: 10.1212/01.wnl.0000312381.29287.ffPMID: 18401019

Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents.

Ward RJ, Lallemand F, de Witte P, Dexter DT.

Prog Neurobiol · 2008-04-04

DOI: 10.1016/j.pneurobio.2008.03.003PMID: 18482793

Absence of cognitive deficits following deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.

Fraraccio M, Ptito A, Sadikot A, Panisset M, Dagher A.

Arch Clin Neuropsychol · 2008-04-03

DOI: 10.1016/j.acn.2008.02.001PMID: 18394859

Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like

QUIK MARYKA, MONTE DONATO DI, LANGSTON J WILLIAM.

· 2008-04-02

Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies.

Liu J, Hong Z, Ding J, Liu J, Zhang J, Chen S.

J Proteome Res · 2008-04-02

DOI: 10.1021/pr7007779PMID: 18380473

Towards gene therapy for Parkinson's disease.

Palfi S.

Lancet Neurol · 2008-04-02

DOI: 10.1016/s1474-4422(08)70066-8PMID: 18387851

The variability of levodopa response in Parkinson's disease: is sensitization reversible?

Jabre MG, Bejjani BP.

Mov Disord · 2008-04-01

DOI: 10.1002/mds.21893PMID: 18163452